Market Overview

CAR-T Therapies Market, 2018-2030 - Review and Quantify Future Opportunities -


The "CAR-T
Therapies Market, 2018-2030"
report has been added to's

The "CAR-T Therapies Market, 2018-2030" report features an extensive
study of the current market landscape and the future potential of CAR-T
therapies. One of the key objectives of the study was to review and
quantify the future opportunities associated with the ongoing
development programs of both small and big pharmaceutical firms.

Amidst the current initiatives to develop more targeted anti-cancer
therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged
as a potent and viable therapeutic intervention to eradicate tumor
cells, with minimal side effects. It is based on the principle of
harnessing the innate potential of the immune system to target and
destroy diseased cells. There are certain key characteristics that
render CAR-T cells suitable for use as effective therapeutic tools;
these include target specificity, adaptability and the capability to
retain immunologic memory.

Close to 70 academic and research institutes across the globe have made
significant contributions to this field, mostly by convening the initial
research on potential product candidates. These efforts have built the
intellectual framework for the establishment of several start-ups. The
ongoing innovation has also led to the discovery of several novel
molecular targets, strengthening the research pipelines of various
companies engaged in this domain. Given the recent approval of two CAR-T
therapies, namely Kymriah (Novartis) and Yescarta (Gilead Sciences), and
a robust development pipeline, the CAR-T therapy market also offers
considerable promise to a number of industry stakeholders.

One of the key objectives of the report was to understand the primary
growth drivers and estimate the future size of the market. Based on
parameters, such as target consumer segments, likely adoption rates and
expected pricing, we have provided an informed estimate on the likely
evolution of the market in the short to mid-term and long term, for the
period 2018-2030.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Chimeric Antigen Receptor-T Cell Therapy

5. Emerging Trends On Social Media

6. Market Landscape

7. Key Insights

8. Marketed And Late-Stage Car-T Therapy Profiles

9. Key Therapeutic Areas Car-T Therapies

10. Emerging Technologies

11. Case Study: Cell Therapy Manufacturing

12. T-Cell Immunotherapy: Cost Price Analysis

13. Market Sizing And Opportunity Analysis

14. Promotional Analysis

15. Company Profiles

16. Conclusion

17. Executive Insights

18. Appendix 1: Tabulated Data

19. Appendix 2: List Of Companies And Organizations

Company Profiles

  • Autolus
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Cell Medica
  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Kite Pharma (A Gilead Sciences Company)
  • Novartis
  • Sinobioway Cell Therapy
  • Takara Bio
  • ZIOPHARM Oncology

For more information about this report visit

View Comments and Join the Discussion!